Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomonitoring and multiple myeloma: impact of lenalidomide on immune checkpoint expression
2021-000987-31Phase 4Completed
- Sponsor
- CHU Rennes
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by CHU Rennes. Primary endpoint: HLA-DR expression on medullary T-lymphocytes. Started Mar 2021; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-000987-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000987-31.